Akari Therapeutics Plc
| NASDAQ: AKTX | Healthcare / Biotechnology / United Kingdom |
| 2.98 | +0.0806 | +2.78% | Vol 5.85K | 1Y Perf 436.84% |
| Nov 29th, 2023 11:45 DELAYED |
| BID | 2.85 | ASK | 3.49 | ||
| Open | 2.93 | Previous Close | 2.90 | ||
| Pre-Market | - | After-Market | 2.94 | ||
| - - | -0.04 -1.36% |
| Target Price | 2.75 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -7.74 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.88 | Earnings Rating | Neutral | |
| Market Cap | 15.07M | Earnings Date | 3rd Oct 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.23 | |
| Beta | 1.23 |
Today's Price Range 2.903.05 | 52W Range 2.8112.00 | 5 Year PE Ratio Range -1.60-1.50 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.65% | ||
| 1 Month | -19.44% | ||
| 3 Months | -11.55% | ||
| 6 Months | 1 507.66% | ||
| 1 Year | 436.84% | ||
| 3 Years | 86.29% | ||
| 5 Years | 66.51% | ||
| 10 Years | 398.43% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -103.77 | |||
ROE last 12 Months | -371.99 | |||
ROA (5Y Avg) | -78.24 | |||
ROA last 12 Months | -231.42 | |||
ROC (5Y Avg) | -380.36 | |||
ROC last 12 Months | -365.34 | |||
Return on invested Capital Q | -51.08 | |||
Return on invested Capital Y | -68.47 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.50 | ||||
| 3.74 | ||||
| - | ||||
| - | ||||
| -2.30 | ||||
| -0.39 | ||||
| 3.75 | ||||
| 0.14 | ||||
| 23.02M | ||||
| Forward PE | -53.87 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.70 | ||||
| 3.70 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2021 | - | -0.03 | - |
| Q02 2021 | - | -0.11 | - |
| Q01 2021 | - | -0.15 | - |
| Q04 2020 | - | -0.22 | - |
| Q03 2020 | 0.00 | 0.04 | - |
| Q02 2020 | 0.00 | -0.28 | - |
| Q01 2020 | 0.00 | -0.13 | - |
| Q04 2019 | 0.00 | -0.37 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | 0.00 | - | - |
| 12/2023 QR | 0.00 | - | - |
| 12/2023 FY | 0.00 | - | - |
| 12/2024 FY | 0.00 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 5.85K |
| Shares Outstanding | 5.06K |
| Shares Float | 2.90M |
| Trades Count | 90 |
| Dollar Volume | 17.27K |
| Avg. Volume | 11.36K |
| Avg. Weekly Volume | 10.92K |
| Avg. Monthly Volume | 8.26K |
| Avg. Quarterly Volume | 14.91K |
Akari Therapeutics Plc (NASDAQ: AKTX) stock closed at 2.9806 per share at the end of the most recent trading day (a 2.78% change compared to the prior day closing price) with a volume of 5.85K shares and market capitalization of 15.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Akari Therapeutics Plc CEO is Clive Richardson.
The one-year performance of Akari Therapeutics Plc stock is 436.84%, while year-to-date (YTD) performance is 534.31%. AKTX stock has a five-year performance of 66.51%. Its 52-week range is between 2.808 and 12, which gives AKTX stock a 52-week price range ratio of 1.88%
Akari Therapeutics Plc currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 3.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -231.42%, a ROC of -365.34% and a ROE of -371.99%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Akari Therapeutics Plc, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akari Therapeutics Plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Akari Therapeutics Plc is Strong Buy (1), with a target price of $2.75, which is -7.74% compared to the current price. The earnings rating for Akari Therapeutics Plc stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akari Therapeutics Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akari Therapeutics Plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.69, ATR14 : 0.28, CCI20 : -160.28, Chaikin Money Flow : -0.31, MACD : -0.15, Money Flow Index : 14.58, ROC : -17.61, RSI : 32.23, STOCH (14,3) : 6.41, STOCH RSI : 0.00, UO : 27.35, Williams %R : -93.59), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akari Therapeutics Plc in the last 12-months were:
Akari Therapeutics Plc
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.
CEO: Clive Richardson
Telephone: +44 2080040270
Address: 75/76 Wimpole Street, London W1G 9RT, , GB
Number of employees: 10
